Dr. He Ruyi is a leading authoritative expert in the field of clinical development and regulatory regimes in China. Prior to RemeGen, Dr. He served as the Chief Scientist of the Center for Drug Evaluation (CDE) of the NMPA (National Medical Products Administration of China) where he played a major role in the implementation of policy reforms for clinical trials in China. For 17 years from 1999 to 2016, Dr. He served at the U.S. Food and Drug Administration (FDA) in various roles including as Deputy Division Director. During his tenure at FDA, Dr. He was involved in FDA guidance development in multiple therapeutic areas and was responsible for approving numerous applications for investigational new drugs (INDs) and new drug applications (NDAs). Dr. He is a licensed, board-certified physician in Internal Medicine in Maryland, USA. Dr. He received a M.D. from China Medical University and completed residency training in internal medicine at Howard University Hospital in Washington D.C.